Thermo Fisher Scientific Inc.

TMO · NYSE · USD

Can Thermo Fisher turn a biotech funding recovery and reshoring demand into durable mid-single-digit organic growth while absorbing tariffs, inflation and acquisition debt?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Biotech funding recovery

    The bull case is that biotech funding has turned and customer spending is converting into orders, so pharma and biotech revenue can keep building from here.

  • Bioproduction share gains

    Bioproduction is growing faster than competitors report, and reshoring of drug production should add equipment and consumable demand as new U.S. plants are built.

  • Services and clinical research

    Clinical research authorizations, the Accelerator offering and the Clario purchase give Thermo Fisher a services franchise that customers rarely split among several suppliers.

  • Productivity offsets costs

    Management has repeatedly absorbed tariffs, currency swings and mix pressure through cost productivity, which is why earnings have grown faster than revenue.

Bear case

  • Academic funding not normal

    The bear case is that U.S. academic and government spending stays below normal and instrument sales never return to prior levels even after the federal budget passes.

  • Back-half pharma services

    A large share of expected growth sits in the second half, tied to pharma services production schedules that can slip if customer campaigns move.

  • Tariffs and inflation

    Tariffs, a stronger dollar and oil-driven cost inflation can hit margins faster than the company's productivity programs remove the cost.

  • Acquisition integration and debt

    Growth now depends more on acquisitions, which bring integration work, added debt and near-term earnings dilution before synergies arrive.

Bull and bear points

Growth & Execution

In short: Organic guidance moved to the top of its range, but results lean on second-half pharma services volume.

Bull · 2

  • Organic growth guidance raised to top of range

    In January management guided to slightly above 3% organic growth and said it would retire risk through the year; it now expects about 4%, at the top of the range.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Bioproduction outgrows peers and gains from reshoring

    Management says bioproduction grew well above what competitors reported, and that reshoring revenue in bioproduction lands mainly in 2027 and 2028 as new U.S. plants are equipped.

    Q1 FY2026 call
Bear · 2

  • Pharma services revenue is weighted to the second half

    Guidance steps organic growth up in the second half, and pharma services production schedules and customer campaigns decide whether that step-up actually arrives.

    Q2 FY2026 call

  • Instrument demand from academia remains below normal

    Sales of instruments to academic and government customers in the U.S. and China stayed muted, and management says it will not call a new trend from one good quarter.

    Q1 FY2026 call

Profitability & Financial Strength

In short: Margins and cash flow are strong, while inflation and Clario-related debt weigh on earnings.

Bull · 2

  • Operating margin expands despite acquisition dilution

    Operating margin was 18.6% in the latest quarter, 1.2 points above a year earlier, as volume leverage and cost productivity covered the dilution from newly acquired businesses.

    Filed financials

  • Free cash flow covers buybacks and dividend

    Free cash flow was $7.6 billion over the past year, 16% of revenue, which funds the share repurchases and the raised dividend without straining the balance sheet.

    Filed financials
Bear · 2

  • Inflation placeholder added to 2026 guidance

    In January guidance assumed only the tariffs already in place; by April management had added an explicit buffer for oil-driven inflation it may not fully offset within the year.

    Tone shiftQ4 FY2025 → Q1 FY2026

  • Net debt rises with the Clario acquisition

    Net debt rose to $35.3 billion from $32.1 billion a year earlier after the Clario purchase, while the earlier acquisitions still dilute 2026 earnings until their synergies arrive.

    Filed financials

Market Position

In short: Recurring services and China growth support share gains, while tariffs and U.S. federal budgets set the risk.

Bull · 2

  • China returns to low single-digit growth

    China, about 7.5% of revenue, declined through 2025 on pricing and reimbursement pressure; in the second quarter it grew again on pharma, biotech and industrial demand, though academic spending there is still muted.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Services provide a recurring revenue base

    Services were 43% of revenue in Q2 FY2026, and that recurring base plus consumables makes results less dependent on capital equipment orders when academic budgets tighten.

    Filed financials
Bear · 2

  • Tariffs and trade policy raise costs

    Tariffs between the U.S. and Europe and related currency moves have repeatedly cost the company margin, and guidance only assumes tariffs currently in place, so new measures would need more offsetting.

    10-K, filed 2026-02-26

  • Revenue depends on federal research budgets

    Academic and government customers buy on budget cycles, so a late federal budget or another shutdown delays instrument and consumable orders across the analytical and lab products businesses.

    10-K, filed 2026-02-26